Literature DB >> 17064636

Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient.

Arlo Upton1, Kieren A Marr.   

Abstract

Infection due to opportunistic moulds is an emerging problem in hematopoietic stem cell recipients. Through the 1990s, the incidence of invasive aspergillosis in allogenic graft recipients climbed steadily, peaking at 10% to 15%. In this decade, other opportunistic mould infections are emerging, including zygomycosis, fusariosis, and scedosporiosis. These epidemiologic changes are likely due to greater or different types of host immune suppression, medical interventions such as antifungal prophylaxis, and more successful treatment of aspergillosis, keeping immunosuppressed patients alive and at risk. The non-Aspergillus moulds generally exhibit variable susceptibility to antifungal agents, and outcomes continue to be disappointing. Thus, prevention of infection becomes a prominent concern in the care of these patients.

Entities:  

Year:  2006        PMID: 17064636     DOI: 10.1007/s11908-006-0017-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  49 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Polyphasic taxonomy of Aspergillus fumigatus and related species.

Authors:  Seung-Beom Hong; Seung-Joo Go; Hyeon-Dong Shin; Jens C Frisvad; Robert A Samson
Journal:  Mycologia       Date:  2005 Nov-Dec       Impact factor: 2.696

3.  Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Authors:  Stéphane Vigouroux; Odile Morin; Philippe Moreau; Françoise Méchinaud; Nadine Morineau; Béatrice Mahé; Patrice Chevallier; Thierry Guillaume; Viviane Dubruille; Jean-Luc Harousseau; Noël Milpied
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

4.  PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue.

Authors:  R Bialek; F Konrad; J Kern; C Aepinus; L Cecenas; G M Gonzalez; G Just-Nübling; B Willinger; E Presterl; C Lass-Flörl; V Rickerts
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

5.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

6.  The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.

Authors:  J R Perfect; G M Cox; J Y Lee; C A Kauffman; L de Repentigny; S W Chapman; V A Morrison; P Pappas; J W Hiemenz; D A Stevens
Journal:  Clin Infect Dis       Date:  2001-10-22       Impact factor: 9.079

7.  In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

Review 8.  Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.

Authors:  W J Steinbach; W A Schell; J L Miller; J R Perfect; P L Martin
Journal:  J Infect       Date:  2004-01       Impact factor: 6.072

9.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors:  Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

10.  Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

Authors:  Marcio Nucci; Elias J Anaissie; Flavio Queiroz-Telles; Carlos A Martins; Plínio Trabasso; Cristiana Solza; Claudia Mangini; Belinda P Simões; Arnaldo L Colombo; Jorge Vaz; Carlos E Levy; Silvia Costa; Vaneusa A Moreira; José Salvador Oliveira; Nestor Paraguay; Gisele Duboc; Julio C Voltarelli; Angelo Maiolino; Ricardo Pasquini; Cármino A Souza
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

View more
  7 in total

Review 1.  Universal fungal vaccines: could there be light at the end of the tunnel?

Authors:  Mawieh Hamad
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

2.  Fusarium keratitis at a tertiary eye care centre in India.

Authors:  Sujata Das; Savitri Sharma; Samir Mahapatra; Srikant K Sahu
Journal:  Int Ophthalmol       Date:  2014-06-15       Impact factor: 2.031

Review 3.  Fungal infections of the lung in children.

Authors:  Paolo Toma; Alice Bertaina; Elio Castagnola; Giovanna Stefania Colafati; Maria Luisa D'Andrea; Andrea Finocchi; Vincenzina Lucidi; Angela Mastronuzzi; Claudio Granata
Journal:  Pediatr Radiol       Date:  2016-09-23

4.  Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Cornelia Lass-Flörl; Astrid Mayr; Susanne Perkhofer; Guido Hinterberger; Johann Hausdorfer; Cornelia Speth; Manfred Fille
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

5.  The putative alpha-1,2-mannosyltransferase AfMnt1 of the opportunistic fungal pathogen Aspergillus fumigatus is required for cell wall stability and full virulence.

Authors:  Johannes Wagener; Bernd Echtenacher; Manfred Rohde; Andrea Kotz; Sven Krappmann; Jürgen Heesemann; Frank Ebel
Journal:  Eukaryot Cell       Date:  2008-08-15

6.  Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.

Authors:  Jin Seok Kim; June-Won Cheong; Ho Jin Shin; Jong Wook Lee; Je-Hwan Lee; Deok-Hwan Yang; Won Sik Lee; Hawk Kim; Joon Seong Park; Sung-Hyun Kim; Yang Soo Kim; Jae-Yong Kwak; Yee Soo Chae; Jinny Park; Young Rok Do; Yoo Hong Min
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

7.  Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia.

Authors:  Elias Seyoum; Adane Bitew; Amete Mihret
Journal:  BMC Infect Dis       Date:  2020-03-19       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.